Alcon Inc. (0A0D.L)
| Previous close | 71.77 |
| Open | 72.10 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 71.58 - 72.10 |
| 52-week range | 55.26 - 75.36 |
| Volume | |
| Avg. volume | 118,419 |
| Market cap | 34.563B |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | 0.79 |
| EPS (TTM) | 0.91 |
| Earnings date | 20 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireAlcon’s Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance
GENEVA, June 24, 2024--Alcon’s Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance
Globe NewswireOculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: O
Business WireAlcon Reports Strong First-Quarter 2024 Results Driven by Robust Sales in Contact Lenses and Ocular Health
GENEVA, May 13, 2024--Alcon Reports Strong First-Quarter 2024 Results Driven by Robust Sales in Contact Lenses and Ocular Health
